Incannex Healthcare Inc. (IXHL)
| Market Cap | 43.55M -19.8% |
| Revenue (ttm) | n/a +616.7% |
| Net Income | -48.41M |
| EPS | -5.22 |
| Shares Out | 11.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 92,151 |
| Open | 3.580 |
| Previous Close | 3.590 |
| Day's Range | 3.420 - 3.720 |
| 52-Week Range | 2.490 - 20.313 |
| Beta | 2.82 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 2, 2026 |
About IXHL
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixe... [Read more]
Financial Performance
In fiscal year 2025, Incannex Healthcare's revenue was $86,000, an increase of 616.67% compared to the previous year's $12,000. Losses were -$46.89 million, 154.0% more than in 2024.
Financial StatementsNews
Incannex doses first patient in DReAMzz study
Incannex (IXHL) provided a corporate update reporting the dosing of the first patient in its DReAMzz Phase 2 study of IHL-42X in obstructive sleep apnea, the grant of a U.S.
Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position
Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apnea U.S. composition and methods of treatment patent granted covering IHL-42X with baseline ex...
Incannex doses first patient in DReAMzz study of IHL-42X
Incannex (IXHL) announced that the first patient has been dosed in the DReAMzz Phase 2 dose-optimization study of IHL-42X, the company’s oral fixed-dose combination drug candidate for the treatment of...
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation Fi...
Incannex receives additional A$5.1M R&D tax incentive refund
Incannex (IXHL) Healthcare announced it has received the final A$5.1M refund under the Australian Government’s Research and Development Tax Incentive Program following approval of the company’s overse...
Incannex commences screening in DReAMzz trial
Incannex (IXHL) announced that participant screening has commenced in the company’s DReAMzz Phase 2 dose confirmation study evaluating IHL-42X for the treatment of obstructive sleep apnea. IHL-42X has...
Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea
MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innova...
Incannex granted IHL-42X composition patent by USPTO
Incannex (IXHL) announced that the United States Patent and Trademark Office, or USPTO, has granted a patent titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea.” The granted pat...
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
MELBOURNE, Australia and NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innova...
Incannex receives A$6.04M tax incentive refund
Incannex (IXHL) announced that it has received A$6.04M under the Australian Government’s Research and Development Tax Incentive Program. The company also expects to receive an additional approximately...
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
In addition to the A$6.0 million refund received, the Company expects a further approximately A$5.1 million in R&D Tax Incentive proceeds later this year, bringing total expected non-dilutive funding ...
Incannex Announces Initiation of Research Coverage by Alliance Global Partners
MELBOURNE, Australia and NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovat...
Incannex initiated with a Buy at Alliance Global
Alliance Global analyst James Molloy initiated coverage of Incannex (IXHL) with a Buy rating and $18 price target based primarily on expectations for lead programs IHL-42X for obstructive sleep apnea…
Incannex Healthcare Quarterly report: Q3 2026
Incannex Healthcare has published its Q3 2026 quarterly earnings report on May 15, 2026.
Incannex commences DReaMzz clinical study of IHL-42X in OSA
Incannex (IXHL) Healthcare announced the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea. The Company has now completed extensive si...
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
Major operational milestone achieved as Incannex advances late-stage development of IHL-42X, with all clinical sites identified and trial infrastructure activated Major operational milestone achieved ...
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development
MELBOURNE, Australia and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for h...
Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough
Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital ...
Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness
MELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, t...
Incannex reactivates share repurchase program
Incannex (IXHL) announced that it has reactivated its previously approved share repurchase program, with the program having been active over the past two trading days. The company has utilized the…
Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position
Board initiates buyback activity following period of inactivity, with repurchases executed over the past two trading days Board initiates buyback activity following period of inactivity, with repurcha...
Incannex enters partnership agreement with American Academy of Sleep Medicine
Incannex (IXHL) announced it has entered into a partnership agreement with the American Academy of Sleep Medicine, or AASM, Foundation. Through this partnership, Incannex has joined the AASM Foundatio...
Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research
MELBOURNE, Australia and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impa...
Incannex reports balance sheet with $75M in cash, no debt
Incannex (IXHL) Healthcare reported that it holds approximately $75 million in cash with no debt, following the completion of its recently announced financing led by dedicated healthcare-focused insti...
Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development
MELBOURNE, Australia and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impa...